Copenhagen – AfricaNewsAnalysis

Merck to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016

28/09/2016 ANA 0

Merck, a leading science and technology company, today announced that new research from their marketed and pipeline compounds will be presented at this year’s European Society for Medical Oncology (ESMO; October 7–11, 2016, Copenhagen, Denmark) […]

New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients

07/10/2013 ANA 0

Novartis recently announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in patients with relapsing forms of multiple sclerosis (MS), and was associated with a higher […]

Data at ECTRIMS to confirm Novartis’ Gilenya® long-term efficacy on reducing brain volume loss and real-world relapse rates in MS

25/09/2013 ANA 0

New data showing the benefits of Gilenya® (fingolimod) on patient outcomes in multiple sclerosis (MS) will be presented at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) in […]